Oragenics (OGEN) Competitors $1.19 +0.04 (+3.48%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.19 0.00 (-0.34%) As of 06:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. BCTX, JAGX, INDP, CMND, EVAX, REVB, TTNP, NBY, VRAX, and CNSPShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Briacell Therap (BCTX), Jaguar Animal Health (JAGX), Indaptus Therapeutics (INDP), Clearmind Medicine (CMND), Evaxion A/S (EVAX), Revelation Biosciences (REVB), Titan Pharmaceuticals (TTNP), NovaBay Pharmaceuticals (NBY), Virax Biolabs Group (VRAX), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors Briacell Therap Jaguar Animal Health Indaptus Therapeutics Clearmind Medicine Evaxion A/S Revelation Biosciences Titan Pharmaceuticals NovaBay Pharmaceuticals Virax Biolabs Group CNS Pharmaceuticals Briacell Therap (NASDAQ:BCTX) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk. Is BCTX or OGEN more profitable? Briacell Therap's return on equity of -479.97% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets Briacell TherapN/A -479.97% -182.26% Oragenics N/A -2,087.95%-486.56% Which has more risk & volatility, BCTX or OGEN? Briacell Therap has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Does the media prefer BCTX or OGEN? In the previous week, Briacell Therap had 4 more articles in the media than Oragenics. MarketBeat recorded 7 mentions for Briacell Therap and 3 mentions for Oragenics. Oragenics' average media sentiment score of 0.33 beat Briacell Therap's score of 0.26 indicating that Oragenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oragenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, BCTX or OGEN? Briacell Therap is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriacell TherapN/AN/A-$4.79M-$8.32-0.09OragenicsN/AN/A-$20.66M-$21.42-0.06 Do analysts recommend BCTX or OGEN? Briacell Therap currently has a consensus price target of $32.00, indicating a potential upside of 4,230.18%. Given Briacell Therap's stronger consensus rating and higher probable upside, analysts clearly believe Briacell Therap is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in BCTX or OGEN? 15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 5.7% of Briacell Therap shares are owned by company insiders. Comparatively, 4.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBriacell Therap beats Oragenics on 11 of the 13 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$979K$791.77M$5.61B$21.04BDividend YieldN/A4.84%4.61%3.56%P/E Ratio-0.171.1830.2928.02Price / SalesN/A26.06470.6157.05Price / CashN/A19.5638.2123.95Price / Book1.956.588.865.26Net Income-$20.66M-$4.98M$3.25B$994.11M7 Day Performance2.59%1.86%3.72%2.09%1 Month Performance-11.19%0.45%5.86%2.35%1 Year Performance-97.25%16.14%30.49%13.36% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.3598 of 5 stars$1.19+3.5%N/A-97.8%$979KN/A-0.175News CoverageShort Interest ↓Gap UpBCTXBriacell Therap2.8378 of 5 stars$0.63-18.9%$32.00+4,971.3%-91.1%$4.28MN/A-0.088News CoverageStock SplitShort Interest ↓Gap UpHigh Trading VolumeJAGXJaguar Animal Health2.0145 of 5 stars$2.23-0.2%$60.00+2,596.6%-92.3%$4.25M$11.69M0.0050News CoverageNegative NewsEarnings ReportINDPIndaptus Therapeutics3.2399 of 5 stars$7.35-4.6%$238.00+3,140.3%-83.4%$4.19MN/A-0.186News CoverageEarnings ReportGap DownCMNDClearmind Medicine1.0245 of 5 stars$0.98-0.4%N/A-8.9%$4.17MN/A-0.89N/AShort Interest ↓Gap UpEVAXEvaxion A/S1.8522 of 5 stars$2.76+3.1%$10.00+261.8%-80.0%$3.86M$3.34M-2.3860News CoverageREVBRevelation Biosciences0.1685 of 5 stars$2.49-3.8%N/A-94.0%$3.84MN/A-0.0110Short Interest ↑TTNPTitan Pharmaceuticals0.2895 of 5 stars$3.89-0.8%N/A-8.7%$3.54M$180K-0.8510Earnings ReportShort Interest ↑Gap DownNBYNovaBay Pharmaceuticals1.681 of 5 stars$0.60-2.1%$0.85+42.1%+30.3%$3.48M$9.78M-0.0130Gap DownVRAXVirax Biolabs Group3.4469 of 5 stars$0.78+0.8%$3.00+283.1%-56.8%$3.40M$10K0.005Short Interest ↓CNSPCNS Pharmaceuticals1.6188 of 5 stars$7.47-2.2%$300.00+3,916.1%-92.7%$3.36MN/A0.005News CoverageEarnings ReportShort Interest ↑ Related Companies and Tools Related Companies Briacell Therap Competitors Jaguar Animal Health Competitors Indaptus Therapeutics Competitors Clearmind Medicine Competitors Evaxion A/S Competitors Revelation Biosciences Competitors Titan Pharmaceuticals Competitors NovaBay Pharmaceuticals Competitors Virax Biolabs Group Competitors CNS Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access